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Abstract
Lovastatin is an anti-cholesterol lactone drug indicated for the treatment of hyperlipidemia and to reduce the 
risk of coronary heart disease. It is converted to the β-hydroxy acid form (lovastatin acid) in vivo, which is the major 
pharmacologically active metabolite. Here, we describe the development and validation of an ultra-performance 
liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)-based method utilizing polarity switching for 
the simultaneous quantification of lovastatin and lovastatin acid in human plasma. Simple protein precipitation 
extraction and direct injection of the extracted samples without drying/reconstitution showed good recoveries of 
both analytes (~70%). The developed method exhibited satisfactory intra-day and inter-day accuracy and precision. 
The interconversion between lovastatin and lovastatin acid during sample preparation and storage was minimal (< 
1.9%). The lower limits of quantification were 0.5 and 0.2 nM (or 0.2 and 0.084 ng/mL) for lovastatin and lovastatin 
acid, respectively, using only 50 μL of plasma during extraction. The validated method was successfully applied to 
analyze plasma samples obtained from a healthy human subject who enrolled in a clinical drug interaction study 
involving lovastatin. 
Keywords: Lovastatin; Lovastatin acid; UPLC-MS/MS; Polarity 
switching; Protein precipitation extraction; Pharmacokinetics
Abbreviations: Auc: Area Under The Plasma Concentration-Time 
Curve; Ce: Collision Energy; Cid: Collision-Induced Dissociation; Cmax: 
Maximum Concentration; Cyp: Cytochrome P450; Cv: Coefficient 
Of Variation; Dmso: Dimethyl Sulfoxide; Hmgcr: 3-Hydroxy-3-
Methylglutaryl Coenzyme A Reductase; Hplc-Uv: High-Performance 
Liquid Chromatography-Ultraviolet Detection; Is: Internal Standard; 
Lle: Liquid–Liquid Extraction; Lloq: Lower Limit Of Quantification; 
Lv: Lovastatin; Lva: Lovastatin Acid; Mrm: Multiple Reaction 
Monitoring; Ppe:protein Precipitation Extraction; Qc: Quality Control; 
S.d.: Standard Deviation; Spe: Solid-Phase Extraction; S/N: Signal-
To-Noise Ratio; Sv: Simvastatin; Sva: Simvastatin Acid; T1/2: Terminal 
Elimination Half-Life; Tmax:time To Reach Cmax; Uplc-Ms/Ms: Ultra-
Performance Liquid Chromatography-Tandem Mass Spectrometry
Introduction
Lovastatin (LV) is a member of the class of cholesterol-lowering 
agents known as statins and is indicated for the treatment of 
dyslipidemia and the prevention of coronary heart disease. LV, a 
lactone, is readily hydrolyzed in vivo to form the pharmacologically 
active metabolite lovastatin β-hydroxy acid (LVA), which inhibits 
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), a 
key enzyme in the cholesterol biosynthetic pathway [1]. In human 
liver, LV also is metabolized by cytochrome P450 (CYP) 3A4 to form 
6'-β-hydroxy- and 6'-exomethylene-LV, both of which also are HMGCR 
inhibitors [2,3]. However, neither metabolite is readily detected in vivo. 
Additional LV metabolites (e.g., 3'-hydroxy-LV and conjugates formed 
after β-oxidation of the heptanoic acid moiety of LVA) can be detected 
in vivo, but do not inhibit HMGCR [2]. Therefore, LV and LVA are the 
major drug-derived molecules that can be used for therapeutic drug 
monitoring of LV treatment. Sensitive and specific analytical methods 
for simultaneous measurement of LV and LVA in human plasma are 
needed.
A number of studies have described the development and 
validation of analytical methods for LV. Pasha et al. [4] described an 
HPLC method coupled to UV detection (HPLC-UV), monitoring at a 
wavelength of 237 nm, to separate LV and four other statins. The lower 
limit of quantification (LLOQ) for LV was 0.1 μg/mL (~250 nM). This 
method is useful for pharmaceutical formulation analysis and in vitro 
metabolism studies, but lacks the sensitivity (sub-nM LLOQ) required 
for pharmacokinetic studies. A more sensitive HPLC-UV method, 
which achieved an LLOQ of 1.0 ng/mL (~2.5 nM) for LV, was described 
more recently [5]. However, it requires a relatively large volume (2 
mL) of human plasma. Marked enhancement in sensitivity for LV has 
been achieved by employing tandem mass spectrometric (MS/MS) 
detection with the LLOQ ranging from 0.025 to 0.1 ng/mL (~0.06 to 
0.25 nM) using 0.2-0.5 mL of human plasma [6-9]. However, all sample 
preparation methods were complicated and time-consuming, requiring 
liquid-liquid extraction (LLE) with tert-butyl methyl ether, ethyl 
acetate, ether-methylene chloride or n-hexane-methylene dichloride-
isopropanol, followed by evaporation under nitrogen at an elevated 
temperature (40–50°C). In general, recovery following LLE was 
approximately 85%, but ethyl acetate gave a low of 55%. 
Few reports have described the simultaneous measurement of LV 
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and LVA in human plasma. Sun et al. [10] described a solid-phase 
extraction (SPE)- and HPLC-MS/MS-based analytical method for LV 
and LVA in human plasma, applying the method for a comparative 
pharmacokinetic study of different LV dosage forms. However, the 
report did not provide details of the method (e.g., plasma volume 
used, extraction recovery, ions monitored, matrix effect or stability) 
to allow cross-evaluation. In another report, Wu et al. [11] described 
an SPE- and HPLC-MS/MS-based analytical method for LV and LVA 
in mouse and rat plasma. This method, which used 0.1 mL of plasma, 
had an LLOQ of 0.5 ng/mL (~1.2 nM) and an extraction recovery of 
~55% for LV. HPLC-UV methods [12,13] also have been reported for 
the simultaneous quantification of LV and LVA, exhibiting an LLOQ 
≥ 25 ng/mL (~62 nM). However, in general, these methods lack the 
necessary sensitivity for pharmacokinetic studies. The purpose of the 
study described herein is to develop and validate a simple protein 
precipitation extraction (PPE), direct injection, UPLC-MS/MS-based 




LV was purchased from U.S. Pharmacopeia (Rockville, MD, USA). 
LVA, simvastatin (SV) and simvastatin acid (SVA) were obtained from 
Toronto Research Chemicals Inc. (North York, ON, Canada). SV and 
SVA were used as internal standards (IS) for the quantification of LV 
and LVA, respectively. Ammonium acetate and dimethylsulfoxide 
(DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Optima-grade water, acetonitrile, methanol and acetic acid were 
obtained from Fisher Scientific (Pittsburgh, PA, USA). Blank human 
plasma (collected in K2-EDTA tubes) was purchased from Innovative 
Research (Novi, MI, USA).
Instrument and chromatographic conditions
The UPLC–MS/MS system consisted of a Waters Acquity I-Class 
UPLC and a Xevo TQ-S triple quadrupole mass spectrometer equipped 
with an electrospray ionization (ESI) source (Waters Corporation, 
Milford, MA, USA). Chromatographic separation was achieved using 
an ACQUITY UPLC BEH C18 (1.7 µm, 2.1 x 50 mm) column, which 
was protected by an ACQUITY column in-line filter (0.2 μm). UPLC 
mobile phase (A) consisted of 100% water with 5 mM ammonium 
acetate (pH 4.5), while (B) consisted of acetonitrile-ammonium acetate 
(50 mM; pH 4.5) (90:10, v/v). The pH of each mobile phase (adjusted 
with acetic acid) was selected to minimize interconversion of LV and 
LVA, based on previous observations and recommendations for SV and 
SVA [14,15]. The gradient began with 40% B and was held for 0.5 min. 
Mobile phase B increased linearly to 70% B at 0.8 min, then to 80% B 
at 3.5 min. The column was washed with 100% B for 0.5 min before 
the system was re-equilibrated with 40% B for 1 min prior to the next 
injection. The total run time was 5 min with a flow rate of 0.4 mL/min. 
The autosampler was set at 6°C and the UPLC column heated at 50°C. 
The sample injection volume was 50 µL. 
The mass spectrometer was operated under negative ion mode 
for the first 1.9 min to allow for the detection of LVA and SVA 
(as IS). Instrumental conditions during this time were: capillary 
voltage, 3.10 kV; cone voltage, -32 V; source offset, 50 V; desolvation 
temperature, 500°C; desolvation gas flow, 1000 L/h; cone gas flow, 
150 L/h; nebulizer gas flow, 7.0 bar; and collision gas flow, 0.15 mL/
min. Analyte-specific instrument parameters (i.e., collision energy, 
capillary voltage and cone voltage) were optimized prior to analysis 
using the IntelliStart™ auto-tune with infusion of analyte standards 
(500 nM in methanol at 0.010 mL/min infusion rate, supplemented 
with 50:50 (v/v) mobile phase A:mobile phase B at 0.4 mL/min). 
The specific MRM transitions used for quantification were m/z 
421.4 → 319.3 for LVA and 435.4 → 319.3 for SVA. After 1.9 min, 
the instrument was switched to positive ion mode for the detection 
of LV and SV (as IS). The instrumental conditions were: capillary 
voltage, 1.10 kV; cone voltage, 30 V; source offset, 50 V; desolvation 
temperature, 500°C; desolvation gas flow, 1000 L/h; cone gas flow, 
150 L/h; nebulizer gas flow, 7.0 bar; and collision gas flow, 0.15 mL/
min. Similar to before, analyte-specific instrument parameters were 
optimized prior to analysis using the IntelliStart™ auto-tune with 
infusion of analyte standards (500 nM in methanol at 0.010 mL/min 
infusion rate, supplemented with 50:50 (v/v) mobile phase A:mobile 
phase B at 0.4 mL/min). The specific MRM transitions used for 
quantification were m/z 427.3 → 325.2 for LV as a sodium adduct 
and m/z 441.3 → 325.2 for SV as a sodium adduct. Peak area ratios of 
analyte vs. IS were used to generate calibration curves and calculate 
analyte concentrations in plasma samples.
Preparation of calibration standards and quality controls
Individual stock solutions of LV, LVA, SV, and SVA were prepared by 
dissolving an appropriate amount of each authentic standard in DMSO 
to give a final concentration of 10 mM. These stock solutions were 
stored at -20°C. To prepare working standard stocks, the individual 
stocks were first diluted to 10 µM with methanol and then further 
diluted with methanol to yield working concentrations that were 50-
fold higher than the intended final concentrations in plasma. Working 
standard stocks were prepared fresh from the 10 µM stocks and were 
not stored after being used to prepare calibration standards and QCs. 
Calibration standards were generated by spiking 1.0 µL of working 
standard stock into 49 µL blank human plasma, yielding the following 
final concentrations: 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50 and 100 nM for LV. 
Similarly, a separate set of calibration standards was prepared for LVA. 
LV and LVA quality controls (QCs) also were prepared separately from 
the individual stock solutions to give final concentrations of 2, 10, 50 
and 100 nM LV or LVA in human plasma. Calibration standards were 
prepared in triplicate and QCs in quadruplicate. All were processed as 
plasma samples prior to UPLC-MS/MS analysis.
Sample preparation by protein precipitation extraction 
Each plasma sample (50 µL), including calibration standards and 
QCs, was thawed at room temperature and immediately placed on ice. 
Fifty µL of ice-cold sodium acetate buffer (100 mM; pH 4.5 at room 
temperature) was added to minimize the interconversion of LV and LVA 
during sample preparation. Proteins in the mixture were precipitated 
and extracted with ice-cold methanol (200 µL) containing 0.1% (v/v) 
acetic acid and 3 nM each of SV and SVA as IS. After vortexing for 
10 s, the samples were centrifuged at 2250 g for 15 min at 4°C. The 
supernatant (180 µL) was transferred to 96-well polypropylene plates, 
from which an aliquot (50 µL) of sample was injected for UPLC-MS/
MS analysis.
Method validation
The specificity of the method was investigated by comparing UPLC-
MS/MS extracted ion chromatograms of blank plasma to blank plasma 
spiked with working standard stocks at the LLOQ. The LLOQ was 
defined as the lowest concentration of calibration standards that had 
a signal-to-noise ratio (S/N) greater than 5, an accuracy of 80-120%, 
and an imprecision of ≤ 20%. The limit of detection (LOD) was defined 
as the lowest concentration of calibration standards that resulted in an 
S/N of at least 3.
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The extent of interconversion between LV (lactone) and LVA 
(β-hydroxy acid) that would occur during sample preparation and 
storage was evaluated by quantifying both LV and LVA present in 
freshly made 50 and 100 nM LV-only and LVA-only QC samples. 
These QC samples were analyzed immediately after preparation and 
again after 24 h of storage in an autosampler at 6°C. Statistical analyses 
were performed using unpaired, two-tailed Student’s t-tests (GraphPad 
Prism 5.04; GraphPad Software, Inc., La Jolla, CA, USA).
The intra-day accuracy and precision were determined by replicate 
analyses of the QCs on the same day. The inter-day accuracy and 
precision were determined by replicate analyses of the QCs on three 
separate days. The accuracy (%) was defined as the closeness of the 
average QC concentration determined by the current method to the 
true QC concentration. The precision (coefficient of variation [CV]; 
%) was defined as the spread of individual measures of multiple QC 
preparations.
The extraction recovery was determined by comparing peak 
area ratios of an analyte vs. IS obtained from QC samples that 
were spiked with analyte prior to extraction to those obtained 
from blank plasma extracts that were spiked with known amounts 
of pure analyte following extraction (represents 100% recovery). 
The extraction recovery was examined at three QC concentrations 
(2, 10 and 50 nM for LV and LVA) and in quadruplicate at each 
concentration.
Matrix effects during the MS/MS analysis were evaluated by 
comparing peak areas of analyte from blank plasma extracts that 
were spiked with known amounts of pure analyte to peak areas from 
samples prepared in the neat solvent (water-100 mM sodium acetate 
[pH 4.5]-methanol containing 0.1% [v/v] acetic acid [50:50:200, v/v/v]) 
with known amounts of pure analyte. The matrix effects were examined 
at three QC concentrations (2, 10 and 50 nM for LV and LVA) and in 
quadruplicate at each concentration. Results were expressed as % signal 
remaining relative to standards in the neat solvent (represents 100% 
signal remaining or no suppression).
Freeze-thaw stability was evaluated by exposing QCs to three freeze 
(-20°C)-thaw (room temperature) cycles before sample preparation. 
Long-term storage stability was evaluated by storing QCs and sodium 
acetate-buffered QCs at -80°C for up to one month. The sodium acetate-
buffered QCs were prepared by mixing QCs with an equal volume of 
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500 
Figure 1: Q1 full-scan mass spectra (MS) and product ion mass spectra (MS/MS) of LV (A) and LVA (B), and the internal standards SV (C) and SVA (D)
 The precursor and product ion pairs selected for MRM detection are shown in boxes. The postulated structure of each also is depicted. The signal intensity for the 
most intense peak is in the upper-left corner of each spectrum. CE, collision energy.
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storage stability were examined at three QC concentrations (2, 10 and 
50 nM for LV and LVA) and in quadruplicate at each concentration. 
Results were expressed as % signal remaining relative to freshly-made 
QCs (represents 100% signal remaining).
Analysis of human plasma samples from a clinical study
Blood samples were obtained from a healthy volunteer who 
participated in a drug-drug interaction clinical study involving 
lovastatin. Lovastatin was given once daily for 14 days. On the 
morning of the 7th day following an overnight fast, the volunteer 
received the 7th dose of lovastatin (40 mg) and a single dose of 
warfarin (10 mg) by mouth simultaneously. Venous blood (5 mL) was 
collected in K2-EDTA Vacutainer
® tubes (BD Biosciences, Franklin 
Lakes, NJ, USA) via an intravenous line at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 
10, 12, and 24 h post-drug administration. Within 1 h after collection, 
blood samples were centrifuged (3000 rpm at 4°C for 10 min) and 
the resulting plasma samples transferred to pre-labeled cryotubes for 
storage at -80°C until analysis. The clinical study (ClinicalTrials.gov 
registry number: NCT01250535) was approved by the Institutional 
Review Board of the University of North Carolina at Chapel Hill 
(Chapel Hill, NC, USA). The area under the plasma concentration–
time curve (AUC), terminal elimination half-life (t1/2), maximum 
plasma drug concentration (Cmax), and the time to reach Cmax (Tmax) 
were calculated using the trapezoidal rule–extrapolation method 
and non-compartmental analysis (Phoenix WinNonlin Version 6.3; 
Pharsight, Mountain View, CA, USA). 
Results and Discussion
UPLC–MS/MS analysis
Apostolou et al. [16] previously reported that ESI was more sensitive 
for both SV and SVA than atmospheric pressure chemical ionization 
(APCI). Due to the structural similarity between LV/LVA and SV/SVA 
(Figure 1), ESI was selected for method development in this study. 
Under positive ion mode, LV and SV produced molecular ions at m/z 
427.3 and 441.3, indicating the formation of sodium adducts with 
little protonated ions detected (Figures 1A and 1C). Upon collision-
induced dissociation (CID) fragmentation, three major product ions 
were observed for both LV and SV (m/z 295.2, 310.2 and 325.2). The 
MRM transitions m/z 427.3→325.2 and 441.3→325.2 were selected for 
monitoring LV and SV, respectively. Under negative ion mode, LVA 
and SVA produced molecular ions at m/z 421.4 and 435.3, indicating 
deprotonated anions (Figures 1B and 1D). Upon CID fragmentation, 
two major product ions were observed for both LVA (m/z 319.3 and 
101.0) and SVA (m/z 319.3 and 115.0). The MRM transitions m/z 
421.4→319.3 and 435.3→319.3 were selected for monitoring LVA and 
SVA, respectively. These precursor and product ions for LV/LVA and SV/
SVA also were observed in earlier studies [6,11], although protonated 
lactone cations and acetonitrile-sodium adducts of the lactones were 
predominant in other studies [16-18].
Representative extracted ion chromatograms of blank human 
plasma and calibration standards at LLOQ are shown in Figure 2. Since 
LV and LVA may undergo interconversion during MS analysis (i.e., 
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Figure 2: Representative extracted ion chromatograms of LV (A) and LVA (B) calibration standards at LLOQ in human plasma (upper panel) and blank 
human plasma (lower panel)
The monitored MRM transitions and signal intensity for the most intense peak are shown in the upper-left and upper-right corners of each chromatogram, respectively.
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in-source conversion), chromatographic resolution of LV from LVA 
is required to detect and monitor the extent of such interconversion 
[19]. Chromatographic resolution of SV from SVA also is required 
for the same reason. Upon chromatographic separation, LV and LVA 
eluted at 2.06 and 1.56 min, while SV and SVA eluted at 2.34 and 1.69 
min (Figures 2 and 3). All are well-resolved from each other. Retention 
times did not drift after repeat injections (n=3 ; S.D. ≤ 0.3 s) of the same 
QC samples separated by 30 injections (data not shown). 
Calibration standards, accuracy and precision
A linear calibration curve (0.2-100 nM or 0.084-42 ng/mL) with 
1/x weighting was obtained for LVA, while a quadratic calibration curve 
(0.5-100 nM or 0.2- 40 ng/mL) with 1/x weighting was obtained for 
LV. Coefficients of determination (r2) were greater than 0.99 for the 
calibration curves. Standards with concentrations greater than 100 
nM were not tested because LV and LVA plasma concentrations are 
not expected to exceed 100 nM following a therapeutic dose of LV (40 
mg once daily in this study). The on-column sensitivity of the method 
was 25 and 10 fmol (or 2.8 and 1.2 pg) for LV and LVA, respectively. 
For QC samples at the low, medium, and high concentration, the intra-
day accuracy were range from 97.7-104.9% for LV and 94.5-103.6% for 
LVA, and the inter-day accuracy were range from 98.2-105.3% for LV 
and 95.7-99.5% for LVA (Table 1). The precision was determined by 
calculating CV for QC. The intra-day precision and inter-day precision 
were all within 10% for LV and LVA. These values are well within the 
criteria of 15% bias and 15% CV stated in the US FDA bioanalytical 
method validation guidance [20].
Method validation
Interconversion of LV and LVA during sample preparation and 
storage was examined by monitoring both LV and LVA in single-
component QC samples (50 and 100 nM). Immediately after sample 
preparation, a small amount of LVA was detected in the LV-only QC 
samples with the LVA concentration representing an average 1.7% of the 
LV concentration (Table 2). Similarly, a small amount of LV was detected 
in the LVA-only QC samples with the LV concentration representing 
an average 1.1% of the LVA concentration (Table 3). Upon storage in 
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Figure 3: Representative extracted ion chromatograms of LV and LVA, as well as the internal standards SV and SVA, in a human plasma sample collected 
4 h post-lovastatin administration
The monitored MRM transitions and signal intensity for the most intense peak are shown in the upper-left and upper-right corners of each chromatogram, respectively.










LV 2 104.9 2.9 105.3 6.8
10 99.9 3.4 102.7 3.2
50 97.7 7.8 98.2 0.4
LVA 2 103.6 4.8 98.5 3.7
10 94.5 1.7 99.5 4.1
 50 94.6 9.8 95.7 2.9
CV, coefficient of variance




LVA LVA after 24-h storage
Concentration 
(nM)





Relative to QC 
Concentration 
(%)
50 1.3 2.6 1.1 2.2
50 1.1 2.2 1.2 2.4
50 0.8 1.6 1.6 3.2
100 0.9 0.9 1.2 1.2
100 1.6 1.6 1.6 1.6
100 1.2 1.2 0.6 0.6
Table 2: Conversion of LV to LVA during sample preparation and storage in 
autosampler.
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the autosampler at 6°C for 24 h, the same processed QC samples were 
analyzed again. The extent of LV-LVA conversion (<1.9%; Tables 2 and 
3) did not exhibit statistically significant increases after storage. 
The extraction recoveries of LV and LVA from human plasma 
following PPE were 67-74% for LV and 70-75% for LVA (Table 4), which 
are comparable to recoveries previously reported for PPE extraction 
with human plasma (52% and 57%, respectively) [18]. Both higher and 
lower extraction recoveries have been reported for LV using an LLE 
method (54.8% [8]; ~86% [6,9]) or SPE method (55% [11]). For SV 
and SVA, higher extraction recoveries have been reported using an SPE 
method (78-89%) [17,21]. Little matrix effect was observed for LVA, 
whereas appreciable signal enhancement was observed for LV in the 
presence of human plasma matrix (Table 4). Since the LV molecular ions 
monitored in our MRM method were sodium adducts, the presence of 
plasma matrix could have favored the formation of sodium adduct ions, 
leading to the observed signal increase compared to the neat solvent. 
Both LV and LVA were stable in the QC samples following three 
freeze-thaw cycles with ≤ 10% reduction in concentration (Table 5), 
although LVA appeared to be slightly less stable than LV (90-93.2% 
vs. 97.3-100.5% remaining). In addition, both LV and LVA were stable 
after long-term storage of plasma QC samples at -80°C (Table 5). No 
appreciable difference between plasma samples stored as is and sodium 
acetate-buffered plasma samples was seen (Table 5), indicating that 
immediate buffering of plasma samples after collection is not necessary. 
Application for pharmacokinetic study in human 
The validated simple PPE-based UPLC–MS/MS method was 
applied for the simultaneous quantification of LV and LVA in human 
plasma samples obtained from a clinical drug-drug interaction 
study involving LV. Representative extracted ion chromatograms 
of LV and LVA for a plasma sample collected 4 h post-lovastatin 
administration are shown in Figure 3. The plasma concentration-
time profiles were plotted for a human subject, who received 40 mg 
lovastatin orally the morning of the study and was monitored for 24 





Freeze-Thaw Stability Remaining after one week (%) Remaining after two week (%) Remaining after one month (%)







LV 2 97.3 4.6 117 107 89 93 114 106
10 98.1 3.0 101 97 87 87 103 89
50 100.5 3.6 91 86 90 84 98 81
LVA 2 90.0 6.7 101 112 106 98 121 107
10 93.2 4.8 86 86 84 88 97 86
 50 91.6 6.7 104 100 97 95 106 101




LV LV after 24-h storage
Concentration 
(nM)





Relative to QC 
Concentration 
(%)
50 0.8 1.6 1.8 3.6
50 0.5 1.0 0.6 1.2
50 0.4 0.8 0.5 1.0
100 1.3 1.3 1.7 1.7
100 1.0 1.0 1.2 1.2
100 1.0 1.0 0.7 0.7
Table 3: Conversion of LVA to LV during sample preparation and storage in 
autosampler.
S.D., standard deviation 














LV 2 73 2.1 155 8.1
10 74 2.6 149 1.9
50 67 4.0 134 1.4
LVA 2 75 9.5 102 9.5
10 70 5.1 101 5.3
 50 71 8.5 95 4.7
 























Figure 4: Plasma concentration-time profiles of LV and LVA for a human subject that received 40 mg of lovastatin orally. 
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are summarized in (Table 6). These values are in agreement with 
those previously reported for LV [10], although a greater exposure 
(i.e., Cmax and AUC) of LVA was observed in our study.
Conclusions
A simple PPE-based, direct injection, UPLC-MS/MS analytical 
method using polarity switching has been developed and validated 
for the simultaneous quantification of LV and LVA in human plasma 
samples. The interconversion of LV and LVA during sample preparation 
and storage was minimized by a lower handling temperature (on ice or 
≤ 6°C) and the use of acidified plasma by addition of sodium acetate 
buffer. The validated method has been successfully applied for the 
quantification of LV and LVA in human plasma samples obtained from 
a clinical drug-drug interaction study involving LV.
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